Background: PB119 (polyethylene glycol exenatide) which is a novel once-weekly subcutaneous GLP-1RA, has good pharmacokinetic properties. As a GLP-1RA, it shows a good safety profile and provides solid glycemic control while doesn’t need dose titration. We aimed to assess the efficacy and safety of PB119 monotherapy in Chinese patients with T2DM.

Methods: In this phase 2 study, we randomly assigned 251 patients (1:1:1:1) to receive 3 doses of PB119 (75ug, 150ug, 200ug) or dose-matched placebo using permuted-block randomization, with a block size of 12 and without stratification. Eligible patients were men or women (aged 18-70 years) with T2DM who had a BMI of 18.5-35.0 kg/m², were on a diet and exercise regimen and untreated at least 3 months prior to screening. The study started with a 4-week placebo run-in period followed by a 12-week treatment period. The primary endpoint was the change in HbA1c from baseline to week 12, which was assessed in all patients who received at least 1 dose of study drug and had both baseline and at least 1 post-baseline HbA1c value. Safety was assessed in all patients who received at least 1 dose of study drug. NCT03520972.

Findings: At the end of week 12, the least squares mean change in HbA1c from baseline was -0.39% (95% CI -0.60 to -0.19) in the placebo group, -1.11% (-1.32 to -0.91) in the 75ug group, -1.57% (-1.78 to -1.37) in the 150ug group and -1.41% (-1.61 to -1.20) in the 200ug group. Compared with the placebo group, the change in HbA1c between baseline and week 12 was significant in all PB119 (p<0.001) groups. Significant reductions in TC and TG were observed in 150ug and 200ug groups (P<0.05), while the reductions in body weight and LDL-C were significant in 200ug group (P<0.05). There were no reports of drug-related serious adverse events or severe hypoglycemia.


M. Xu: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at